Synthesis of 1-/2-substituted-[1,2,3]triazolo[4,5-g]phthalazine-4,9-diones and evaluation of their cytotoxicity and topoisomerase II inhibition

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 8, 2008, Pages 4545-4550

  Kim, Jin Sung ^a   Rhee, Hee Kyung ^a   Park, Hyen Joo ^a   Lee, Sang Kook ^a   Lee, Chong Ock ^b   Park Choo, Hea Young ^a  

^a Ewha Womans University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Cytotoxicity; Topoisomerase II; Triazolophthalazine

Indexed keywords

1 ETHYL 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; 1 ISO BUTYL L 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; 1 ISO PROPYL L 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; 1 METHYL 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; 1 N BUTYL 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; 1 N PROPYL 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; 2 ETHYL 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; 2 ISO BUTYL L 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; 2 ISO PROPYL L 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; 2 METHYL 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; 2 N BUTYL 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; 2 N PROPYL 1H [1,2,3]TRIAZOLO[4,5 G]PHTHALAZINE 4,9 DIONE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; QUINONE DERIVATIVE; SULFORHODAMINE B; UNCLASSIFIED DRUG;

ADDITION REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL;

AZO COMPOUNDS; BENZOQUINONES; CELL LINE, TUMOR; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE II; HUMANS; MOLECULAR STRUCTURE; PHTHALAZINES; RHODAMINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 42149176832     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.02.049     Document Type: Article

References (22)

1. Koyama J. Recent Patents Anti-Infect. Drug Discovery 1 (2006) 113
2. Ross D. Drug Metabo. Rev. 36 (2004) 639
3. Asche C. Mini-Rev. Med. Chem. 5 (2005) 449
4. Martinez R., and Chacon-Garcia L. Curr. Med. Chem. 12 (2005) 127
5. Garbett N.C., and Graves D.E. Curr. Med. Chem. Anti-Cancer Agents 4 (2004) 149
6. Liu L.F. Annu. Rev. Biochem. 58 (1989) 351
7. Martinez R., and Chacon-Garcia L. Cur. Med. Chem. 12 (2005) 127
8. Yoo H.-W., Suh M.-E., and Park S.W. J. Med. Chem. 41 (1998) 4716
9. Suh M.-E., Kang M.-J., Yoo H.-W., Park S.-Y., and Lee C.-O. Bioorg. Med. Chem. 8 (2000) 2079
10. Kim J.S., Lee H.-J., Suh M.-E., Park H.-Y., Lee S.K., Park H.J., Kim C., Park S.W., and Lee C.-O. Bioorg. Med. Chem. 12 (2004) 3683
11. Shaikh I.A., Johnson F., and Grollman A.P. J. Med. Chem. 29 (1986) 1329
12. Moore M.H., Hunter W.N., Langlois D'Estaintot B., and Kennard O. J. Mol. Biol. 206 (1989) 693
13. Pindur U., Haber M., and Sattler K. J. Chem. Educ. 70 (1993) 263
14. Kim J.S., Shin K.J., Kim D.C., Kang Y.K., Kim D.J., Yoo K.H., and Park S.W. Bull. Korean Chem. Soc. 23 (2002) 1425
15. Parrick J., and Ragunathan R. J. Chem. Soc., Perkin Trans 1 2 (1993) 211
16. Buckle D.R., and Rockell C.J.M. J. Chem. Soc., Perkin Trans 1 2 (1982) 627-630
17. Buckle D.R., Smith H., Spicer B.A., and Tedder J.M. J. Med. Chem. 26 (1983) 714
18. Lee S.K., Cui B., Mehta R.R., Kinghorn A.D., and Pezzuto J.M. Chem. Biol. Interact. 115 (1998) 215
19. Park H.J., Lee H.-J., Lee E.-J., Hwang H.J., Shin S.-H., Suh M.-E., Kim C., Kim H.J., Seo E.-K., and Lee S.K. Biosci. Biotechnol. Biochem. 67 (2003) 1944
20. Park H.J., Kim Y.-S., Kim J.S., Lee E.-J., Yi Y.-J., Hwang H.J., Suh M.-E., Ryu C.-K., and Lee S.K. Bioorg. Med. Chem. Lett. 14 (2004) 3385
21. Baldwin E.L., and Osheroff N. Curr. Med. Chem. Anti-Cancer Agents 5 (2005) 363
22. Giles G.I., and Sharma R.P. Med. Chem. 1 (2005) 383